Examkin

Question

Difficulty: HardMonitoring and Treatment Evaluation

A 32-year-old woman with relapsing-remitting multiple sclerosis presents to the clinic to discuss changing her disease-modifying therapy. She has experienced two clinical relapses in the past year while receiving glatiramer acetate. The physician plans to prescribe fingolimod. The patient has no other significant past medical history. She was born outside the United States, has no records of her childhood immunizations, and does not recall having chickenpox. Her physical examination is notable for mild residual weakness in her left lower extremity.

Which of the following baseline evaluations are required prior to initiating this medication? (Select all that apply)

  1. ElectrocardiogramAnswer
  2. Varicella-zoster virus IgG antibody testingAnswer
  3. Ophthalmic evaluationAnswer
  4. D
    John Cunningham (JC) virus antibody assay
  5. E
    Thyroid function testing

Answer

The necessary baseline evaluations prior to initiating fingolimod are an electrocardiogram, varicella-zoster virus IgG antibody testing, and an ophthalmic evaluation.
Fingolimod is an oral sphingosine-1-phosphate receptor modulator. Its initiation requires specific baseline monitoring to mitigate severe, predictable adverse effects. First, an electrocardiogram is required because the drug can cause significant first-dose bradycardia and atrioventricular block. Second, varicella-zoster virus IgG antibody testing is necessary in patients without a confirmed history of chickenpox or vaccination; those who test negative must receive the varicella vaccine before starting therapy due to the risk of severe, disseminated VZV infections. Third, an ophthalmic evaluation is required at baseline and 3 to 4 months after initiation because of the well-documented risk of fingolimod-associated macular edema.

Step-by-Step Solution

1
Identify the planned pharmacotherapy and its unique adverse effect profile.
The physician plans to prescribe fingolimod, an oral sphingosine-1-phosphate (S1P) receptor modulator used for multiple sclerosis.
Different disease-modifying therapies for multiple sclerosis have distinct mechanisms of action that necessitate highly specific baseline screening protocols.
2
Determine the cardiovascular risks associated with the medication.
Fingolimod binds to S1P receptors in the cardiac conduction system, which can cause a transient but significant decrease in heart rate and potential atrioventricular (AV) block.
To establish a baseline and identify any pre-existing conduction abnormalities, an electrocardiogram is strictly required before administering the first dose.
3
Determine the infectious disease risks and immunization requirements.
Because the patient lacks confirmed immunity to varicella (no records, no history of chickenpox), varicella-zoster virus (VZV) IgG antibody testing is necessary.
Fingolimod sequesters lymphocytes in lymph nodes, increasing the risk of severe, disseminated VZV infections. Non-immune patients must be vaccinated and wait one month prior to starting therapy.
4
Determine the ocular risks associated with the medication.
Fingolimod increases the risk of macular edema.
A baseline ophthalmic evaluation (often including macular optical coherence tomography) is required to ensure no pre-existing macular pathology, followed by a repeat evaluation 3 to 4 months after initiation.

Key Concept

Fingolimod initiation requires a baseline electrocardiogram (due to first-dose bradycardia/AV block risk), varicella-zoster virus serology in patients without confirmed immunity (due to severe disseminated infection risk), and an ophthalmic evaluation (due to macular edema risk).
Rate this question

Topics

Monitoring and Treatment Evaluation

More questions from this topic